evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,971 questions · 9,849 findings · 853 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,150 · 11.7%GRADE not reported 3,387 · 34.4%Very low 1,963 · 19.9%Low 1,809 · 18.4%Moderate 1,207 · 12.3%High 333 · 3.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings: Fibrin sealant vs usual care

Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Fibrin sealant changes risk of reoperation or repeat procedure for bleeding within 7 days compared with usual care (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Oral classical immunosuppressants… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in short‐term hair regrowth ≥ 75% compared with placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Incidence of serious adverse events · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher long‐term hair regrowth ≥ 75% (greater than 26 weeks of compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Oral small molecule inhibitors… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral small molecule inhibitors (tofacitinib) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Topical small molecule inhibitors… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

Incidence of serious adverse events · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Topical small molecule inhibitors… changes incidence of serious adverse events compared with placebo (very low certainty).

1 finding from 1 review